132 related articles for article (PubMed ID: 11326302)
1. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease.
Russ C; Lovestone S; Powell JF
Mol Psychiatry; 2001 May; 6(3):320-4. PubMed ID: 11326302
[TBL] [Abstract][Full Text] [Related]
2. Identification of genomic organisation, sequence variants and analysis of the role of the human dishevelled 1 gene in late onset Alzheimer's disease.
Russ C; Lovestone S; Powell JF
Mol Psychiatry; 2002; 7(1):104-9. PubMed ID: 11803455
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter.
Lau KF; Miller CC; Anderton BH; Shaw PC
Genomics; 1999 Sep; 60(2):121-8. PubMed ID: 10486203
[TBL] [Abstract][Full Text] [Related]
4. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
6. GSK3: a possible link between beta amyloid peptide and tau protein.
Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J
Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation.
Baum L; Hansen L; Masliah E; Saitoh T
Mol Chem Neuropathol; 1996; 29(2-3):253-61. PubMed ID: 8971700
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase 3: a drug target for CNS therapies.
Bhat RV; Budd Haeberlein SL; Avila J
J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe.
Capurso C; Solfrizzi V; D'Introno A; Colacicco AM; Capurso SA; Capurso A; Panza F
Exp Gerontol; 2004 Oct; 39(10):1567-73. PubMed ID: 15501028
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease.
Vázquez-Higuera JL; Mateo I; Sánchez-Juan P; Rodríguez-Rodríguez E; Pozueta A; Calero M; Dobato JL; Frank-García A; Valdivieso F; Berciano J; Bullido MJ; Combarros O
J Alzheimers Dis; 2011; 27(2):291-7. PubMed ID: 21811019
[TBL] [Abstract][Full Text] [Related]
11. Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.
Andersson ME; Sjölander A; Andreasen N; Minthon L; Hansson O; Bogdanovic N; Jern C; Jood K; Wallin A; Blennow K; Zetterberg H
Int J Mol Med; 2007 Aug; 20(2):233-9. PubMed ID: 17611642
[TBL] [Abstract][Full Text] [Related]
12. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
13. DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: two novel mutations.
Aldudo J; Bullido MJ; Valdivieso F
Hum Mutat; 1999; 14(5):433-9. PubMed ID: 10533070
[TBL] [Abstract][Full Text] [Related]
14. Gene polymorphism in apolipoprotein E and presenilin-1 in patients with late-onset Alzheimer's disease.
Cui T; Zhou X; Jin W; Zheng F; Cao X
Chin Med J (Engl); 2000 Apr; 113(4):340-4. PubMed ID: 11775232
[TBL] [Abstract][Full Text] [Related]
15. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD.
Riazanskaia N; Lukiw WJ; Grigorenko A; Korovaitseva G; Dvoryanchikov G; Moliaka Y; Nicolaou M; Farrer L; Bazan NG; Rogaev E
Mol Psychiatry; 2002; 7(8):891-8. PubMed ID: 12232783
[TBL] [Abstract][Full Text] [Related]
16. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
Avila J
FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain.
Yamamoto H; Hiragami Y; Murayama M; Ishizuka K; Kawahara M; Takashima A
J Neurochem; 2005 Sep; 94(5):1438-47. PubMed ID: 16000144
[TBL] [Abstract][Full Text] [Related]
18. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease.
Maloney B; Ge YW; Alley GM; Lahiri DK
J Neurochem; 2007 Nov; 103(3):1237-57. PubMed ID: 17854398
[TBL] [Abstract][Full Text] [Related]
19. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease.
Mateo I; Infante J; Llorca J; Rodríguez E; Berciano J; Combarros O
Dement Geriatr Cogn Disord; 2006; 21(4):228-32. PubMed ID: 16428884
[TBL] [Abstract][Full Text] [Related]
20. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
